NIH Licensing Opportunity: A Vaccine Against Polyomavirus-Induced 1) Brain Disease (a natalizumab side effect) and 2) Kidney Disease in Transplant Patients

Share Article

During this webinar, NCI Senior Investigator, Chris Buck, describes how JCV-induced brain disease, and kidney disease in transplant patients, can potentially be treated and prevented through the application of a polyomavirus VLP vaccine.

Polyomavirus are a family of tumour viruses that are known to cause brain and kidney damage in immunosuppressed individuals.

Polyomavirus are a family of tumour viruses that are known to cause brain and kidney damage in immunosuppressed individuals.

The vaccine is likely to qualify for FDA fast-track licensing as VLPs are on average safe and patients possess no other possibilities for preventing this malevolent disease.

One Million Solutions in Health announces an opportunity to license science from the NIH which treats JCV-induced brain disease and kidney disease in transplant patients.

One Million Solutions in Health has partnered with the United States' National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) and is seeking to spread awareness of NIH technologies and advances.

In this One Million Solutions in Health webinar entitled "NIH Licensing Opportunity: A Vaccine Against Polyomavirus-Induced Brain Disease" end users are provided with the opportunity to acquire knowledge about the latest science and technology directly from NIH scientists themselves. Users can also take part in One Million Solutions in Health's exclusive Signature Square process where they are able to assess the innovation, make inquiries and give open feedback to the scientists.

Polyomavirus are a family of tumour viruses that are known to cause brain and kidney damage in immunosuppressed individuals. Many adults regularly shed polyomavirus virions from their skin’s surface and in their urine. While healthy individuals are not known to suffer from this process, immunosuppressed individuals can suffer from brain and kidney damage because of this polyomavirus.

Studies were led on two families of cancer-causing viruses with circular DNA genomes revealing that the polyomavirus coat protein naturally self-assembles into virus-like particles (VLPs) that closely resemble the native virion. Such VLPs were discovered to be extraordinarily powerful immunogens in humans.

Join us in this One Million Solutions in Health webinar to find out how JCV-induced 1) brain disease and 2) kidney disease in transplant patients can potentially be treated and prevented through the application of a polyomavirus VLP vaccine. The NCI has recently been granted patents regarding the use of VLPs as vaccines targeting two human polyomaviruses recognised as JCV and BKV.

The potential of this polyomavirus vaccine is highlighted through patients on varying immunosuppressive therapies, including the successful multiple sclerosis drug natalizumab, who make up a clear-cut market for the polyomavirus vaccine.

The vaccine is likely to qualify for FDA fast-track licensing as VLPs are on average safe, and patients possess no other possibilities for preventing this malevolent disease.

The Technology Evaluation Consortium includes the Signature Square process and consists of organization such as AstraZeneca, AbbVie, Amgen and Allergan, and many others.

ABOUT ONE MILLION SOLUTIONS IN HEALTH
The goal of One Million Solutions in Health™ is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery ... of innovative cures, treatments and preventative measures for patients around the world.

In this next year, we will be reviewing 1000's of new solutions and new scientific discoveries. By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way to accelerate the movement of new solutions and scientific discoveries from the scientist to the patient.

We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. By facilitating efforts to ensure organizations can Connect, Learn + Share, Innovate and Collaborate, our vision is to improve health care delivery, accelerate life sciences research, and share patient and consumer-focused ideas and solutions.

As a not-for-profit, we welcome your participation and are thrilled to have you be a part of this transformative journey!

ABOUT THE TECHNOLOGY EVALUATION CONSORTIUM

The Technology Evaluation Consortium™ from One Million Solutions in Health™ is dedicated to improving and accelerating life sciences R&D and health care outcomes. The Technology Evaluation Consortium brings together life sciences and/or health care companies and industry vendors or scientists, and other relevant partners (e.g., government and Universities), to evaluate and validate technologies or services in a collaborative environment.

The model empowers technology providers and scientists, and industry end-users, to collectively assess a number of solutions in a cost-effective manner, producing a depth and breadth of results that no company can achieve alone. Our mission is to triage and streamline new technology consideration for the industry and to be the place for the industry to conduct their evaluations and validations.

MEDIA CONTACT:
Dawn Van Dam
Executive Director and CEO
dawn.vandam(at)onemillionsolutionsinhealth.org
http://www.onemillionsolutionsinhealth.org

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dawn Van Dam
@1MilSolutionsIn
since: 04/2012
Follow >
One Million Solutions in Health
since: 06/2012
Like >
One Million Solutions in Health

Follow us on
Visit website